Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

119.39 +2.60 (+2.22%)
Streaming Delayed Price Updated: 12:30 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
36 37 Next >
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant... 
Via Benzinga
Exposures Product Safety
3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates
These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns. 
Via InvestorPlace
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
Via Investor's Business Daily
Exposures Product Safety
Exploring ABBOTT LABORATORIES (NYSE:ABT)s quality characteristics.
Why the quality investor may take a look at ABBOTT LABORATORIES (NYSE:ABT). 
Via Chartmill
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
There is a world of opportunities ahead for this healthcare giant. 
Via The Motley Fool
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Could Abbott Laboratories Stock Help You Become a Millionaire?
Abbott's earnings have soared over the past decade. 
Via The Motley Fool
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Peering Into Abbott Laboratories's Recent Short Interest
Via Benzinga
Nearing Retirement? These Stocks Are as Cautious as They Come
Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further. 
Via The Motley Fool
3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade
These stocks don't offer the highest yields, but their payouts are growing fast. 
Via The Motley Fool
3 Blue-Chip Stocks to Buy to Bolster Your Portfolio
Delve into three undervalued blue-chip stocks to buy driving growth in consumer staples, pharmaceuticals, and healthcare. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Looking for Growth? 7 Hot Trends That Have Been Flying Under Investors’ Radar.
Discover 7 under-the-radar stock trends set to make waves in the stock market. Find out why savvy investors are tuning in. 
Via InvestorPlace
This Is What Whales Are Betting On Abbott Laboratories
Via Benzinga
Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth
Explore recession-proof stocks thriving in Energy, Health Care, Industrials, and more, offering stability and growth amid economic turmoil. 
Via InvestorPlace
Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade
In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday. 
Via Investor's Business Daily
3 Cash Cows to Boost Your Confidence During the February Chill
The market can be a tricky place. Bet on these cash cow stocks to help restore confidence and extract steady returns. 
Via InvestorPlace
The Smartest Dividend Stocks to Buy With $400 Right Now
These stocks reward you during any market environment. 
Via The Motley Fool
Cardiology's Quantum Leap: FDA's Advisory Panel Gives Thumbs Up To Abbott's Minimally Invasive Heart Valve Repair Device
FDA panel confirms support (13-1) for Abbott Laboratories' TriClip TEER system in treating tricuspid regurgitation. Approval decision expected from FDA in 2024. 
Via Benzinga
Exposures Product Safety
FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom
FDA to review Abbott's TriClip G4 System for severe tricuspid regurgitation. Circulatory System Devices Panel meeting and insights from the briefing document. 
Via Benzinga
Exposures Product Safety
Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.
Abbott Labs has an impressive portfolio of nutrition drinks, and its latest addition could help it profit from a new market: people taking prescribed weight loss drugs. 
Via The Motley Fool
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector. 
Via InvestorPlace
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
There's room for multiple winners in the fast-growing weight-loss market. 
Via The Motley Fool
Abbott Laboratories Stock Getting Closer To Key Technical Benchmark
Abbott Laboratories shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
7 Tremendous Dividend Stocks With Double-Digit 5-Year Growth Rates
When it comes to buying dividend stocks, investors should seek out companies that consistently and repliably grow their payout over time. 
Via InvestorPlace
Want to Get Richer? Here Are the 3 Best Stocks to Buy Now and Hold Forever
Healthcare is an excellent place to find some tried and true wealth compounders. 
Via The Motley Fool
Healthcare And Life Science Funds And ETFs Performance 2023-2024
Healthcare stocks usually provide a defensive posture to a stock portfolio. 
Via Talk Markets
Topics ETFs
2 Stocks to Buy Near Their 52-Week Highs
It's not too late to invest in these stocks. 
Via The Motley Fool
2 Healthcare Dividend Kings to Buy and Hold Forever
It's going to take a lot to interrupt these companies' streaks. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.